Spectranetics announces product reimbursement approval for SLS II

Spectranetics Corporation (Nasdaq:SPNC) today announced that the Ministry of Health, Labor and Welfare in Japan has approved product reimbursement to hospitals for the Spectranetics Laser Sheath (SLS® II), which is used for the removal of problematic pacemaker and defibrillator cardiac leads.

Through the Company's distribution partner, DVx Inc., the initial phase of the product launch will commence immediately and focus on establishing a limited number of lead extraction training centers.

Emile J. Geisenheimer, Chairman, President and Chief Executive Officer, stated, "Japan represents a significant market opportunity for our products. Product reimbursement for our SLS II is an important accomplishment as it is our first product to have both regulatory and reimbursement approval in Japan. We have regulatory submissions pending for certain peripheral atherectomy, crossing solutions, and lead locking device products, and through our partnership with DVx, look forward to offering our full portfolio of products in the future."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How virtual reality transforms women’s labor experiences